click below
click below
Normal Size Small Size show me how
WEEK 23:
Breast cancer treatment:
| Question | Answer |
|---|---|
| digital tomosynthesis | multiple xrays of breasts in may angles creating a 3 dimensional picture of breasts |
| triple assessment (breast and axilla) | history and examination, imagine, and tissue biopsy |
| surgery options in breast (3) | breast conservation surgery, mastectomy, and reconstruction |
| surgery options in axilla (3) | sentinel lymph node biopsy (if node negative), axillary node clearance (if node positive), and targeted axillary dissection (post neoadjuvant patients) |
| when is sentinel lymph node biopsy done | in axilla when node is negative |
| when is axillary node clearance done | in axilla when node positive |
| radiotherapy types (2) | external beam RT (most commonly used) and brachytherapy |
| first line endocrine treatment | SERM ( Selective Estrogen Receptor Modulator) Tamoxifen,Raloxifene Aromatase inhibitors Letrozole,Anastrozole,Exemestane CDK4/6 inhibitors Palbociclib,ribociclib,Abemaciclib |
| second line endocrine treatment | PI3K/AKTmTOR pathway down regulator Everolimus CDK4/6 inhibitors Palbociclib,ribociclib,Abemaciclib |
| targeted therapy (2) | anti HER2 treatment and bone modifying agents |
| anti HER2 treatment as a targeted therapy | Trastuzumab ( Herceptin) Pertuzumab Pertuzumab,Trastuzumab and Hyaluronidase ( PHESGO) Trastuzumab-Emtansine ( Kadcyla) Tyrosine kinase inhibitors Lapatinib, Neratinib |
| bone modifying agents as a targeted therapy | Bisphosphonates ( inhibit osteoclasts): Clodronate, Ibandronate, Zolendronic acid Denosumab: Osteoclast-targeted therapy called a RANK ligand inhibitor |
| gynaecomastia | male breast cancer that can be unilateral/ bilateral and presents as enlargement/ defined mass. Marker of hyperostrogenism and neoplasm needs to be excluded |